Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated:  8/7/2017
The Center for Ortho/ Neuro Care & Research
mi
from
Bend, OR
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated: 8/7/2017
The Center for Ortho/ Neuro Care & Research
mi
from
Bend, OR
Click here to add this to my saved trials
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated:  8/7/2017
ROC Houston, PA
mi
from
Houston, TX
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated: 8/7/2017
ROC Houston, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated:  8/7/2017
Fondren Orthopedic Group, L.L.P.
mi
from
Houston, TX
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated: 8/7/2017
Fondren Orthopedic Group, L.L.P.
mi
from
Houston, TX
Click here to add this to my saved trials
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated:  8/7/2017
Hand Center of San Antonio
mi
from
San Antonio, TX
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
Status: Enrolling
Updated: 8/7/2017
Hand Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated:  8/21/2017
Curtis National Hand Center
mi
from
Baltimore, MD
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated: 8/21/2017
Curtis National Hand Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated:  8/21/2017
University of Michigan
mi
from
Ann Arbor, MI
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated: 8/21/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated:  8/21/2017
Pulvertaft Hand Centre
mi
from
Derby,
Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand
An Outcome Study of Rheumatoid Hand Arthroplasty
Status: Enrolling
Updated: 8/21/2017
Pulvertaft Hand Centre
mi
from
Derby,
Click here to add this to my saved trials
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
Status: Enrolling
Updated:  8/22/2017
Lahey Arlington
mi
from
Arlington, MA
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
Status: Enrolling
Updated: 8/22/2017
Lahey Arlington
mi
from
Arlington, MA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Hemet, CA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Hemet, CA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
La Palma, CA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
La Palma, CA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Ventura, CA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Ventura, CA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Hialeah, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Homestead, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Homestead, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Miami, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Orlando, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Stockbridge, GA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Overland Park, KA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Monroe, LA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Monroe, LA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Worcester, MA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Albuquerque, NM
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Brooklyn, NY
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
New York, NY
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Investigator Sie
mi
from
Charleston, SC
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Investigator Sie
mi
from
Charleston, SC
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Memphis, TN
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Mesquite, TX
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Investigational Site
mi
from
Brussels,
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
ArthroCare, Arthritis Care Research
mi
from
Gilbert, AZ
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
ArthroCare, Arthritis Care Research
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Arizona Research Center
mi
from
Phoenix, AZ
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Arizona Research Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Desert Medical Advances
mi
from
Palm Desert, CA
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
In Vivo Clinical Research
mi
from
Doral, FL
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
In Vivo Clinical Research
mi
from
Doral, FL
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Tampa Medical Group, PA
mi
from
Tampa, FL
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Tampa Medical Group, PA
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Alastair Kennedy, MD
mi
from
Vero Beach, FL
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Alastair Kennedy, MD
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
LaPorte County Institute for Clinical Research Inc.
mi
from
Michigan City, IN
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
LaPorte County Institute for Clinical Research Inc.
mi
from
Michigan City, IN
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Associated Internal Medicine Specialists, PC
mi
from
Battle Creek, MI
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Associated Internal Medicine Specialists, PC
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Saint Paul Rheumatology
mi
from
Eagan, MN
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Saint Paul Rheumatology
mi
from
Eagan, MN
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Physician's East
mi
from
Greenville, NC
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Physician's East
mi
from
Greenville, NC
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Modern Research Associates
mi
from
Dallas, TX
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Modern Research Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Stone Oak Rheumatology
mi
from
San Antonio, TX
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Stone Oak Rheumatology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
TriWest Research Associates
mi
from
La Mesa, CA
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
TriWest Research Associates
mi
from
La Mesa, CA
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Stanford University Medical Center
mi
from
Palo Alto, CA
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Med Investigations/Sierra
mi
from
Roseville, CA
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Med Investigations/Sierra
mi
from
Roseville, CA
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Inland Rheumatology Clinical Trials, Inc.
mi
from
Upland, CA
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Inland Rheumatology Clinical Trials, Inc.
mi
from
Upland, CA
Click here to add this to my saved trials
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/18/2017
Denver Arthritis Clinic
mi
from
Denver, CO
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/18/2017
Denver Arthritis Clinic
mi
from
Denver, CO
Click here to add this to my saved trials